{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"Remained or reduced to <450"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Remained at Baseline level of 450-479"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Increased to 450-479"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Increased to 480-499"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Increased to >=500"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. A lengthened QT interval can be a biomarker for ventricular tachyarrhythmias. The QT interval corrected for heart rate using Bazett's formula (QTcB) was calculated; the faster the heart rate, the shorter the QT interval. Electrocardiogram values (Bazett's QTc value) were summarized using the following reference ranges: \\<450, 450 to 479, 480 to 499, 500 to 549, and \\>550 milliseconds.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population. Only those participants available at the specified time points were analyzed; 3 participants did not have post-Baseline results.","reportingStatus":"POSTED","timeFrame":"From Baseline to investigational product discontinuation (up to 6.230 years)","title":"Number of Participants With a Change From Baseline to the Indicated Worst-case Post-Baseline Bazett's Heart Rate-corrected QT Interval (QTc) Value","type":"PRIMARY","unitOfMeasure":"participants"}